Semaglutide, glucagon, and the hormone signals behind weight loss

What glucagon actually does, and why semaglutide affects it

Your pancreas releases glucagon when blood sugar drops, when you're stressed, or simply between meals. Its job is to signal the liver to push glucose into the bloodstream. That's useful during exercise or fasting. After a meal, though, glucagon should quieten down, and in people with obesity or insulin resistance, it sometimes doesn't, leading to persistent hunger signals and erratic blood-sugar patterns.

GLP-1, a hormone released from your gut after eating, suppresses glucagon naturally. The problem is that the body produces GLP-1 in tiny amounts and breaks it down within minutes. Semaglutide is a synthetic GLP-1 receptor agonist designed to resist that rapid breakdown, so it keeps GLP-1's effects running for a full week from a single injection. According to NHS guidance on semaglutide, the medicine acts on GLP-1 receptors in the pancreas, gut and brain simultaneously, slowing how quickly food leaves the stomach, increasing feelings of fullness, and reducing post-meal glucagon secretion.

The practical upshot is that after eating, blood sugar rises more gradually, glucagon stays lower, and appetite signals are dampened. Many people find that the urge to snack between meals fades considerably, which is distinct from simply deciding to eat less. The biology shifts, not just the willpower.

Trial evidence: what semaglutide's glucagon suppression means in practice

The STEP 1 trial randomised 1,961 adults with obesity (and without type 2 diabetes) to semaglutide 2.4mg or placebo for 68 weeks, alongside lifestyle guidance. The semaglutide group lost an average of around 15% of body weight, versus about 2.4% in the placebo group. Mechanistic analyses from the STEP programme consistently showed reductions in fasting glucagon levels alongside the weight changes, though researchers note that appetite suppression via the brain's GLP-1 receptors is likely the dominant driver of weight loss rather than glucagon suppression alone.

The STEP trials involved thousands of adults across multiple countries, and the results informed both the original NICE appraisal of Wegovy (NICE TA875) and the licensing decisions made by the MHRA. The distinction matters for readers: the evidence base behind Wegovy is substantial and the mechanism is well characterised, not theoretical.

More recently, the Wegovy 7.2mg single-dose pen was approved by the MHRA in April 2026, with trial data showing average weight loss of around 20.7% over 72 weeks at that higher maintenance dose, suggesting that greater GLP-1 receptor engagement, with correspondingly more glucagon suppression, continues to translate into greater average weight reduction. If you want to understand how Wegovy compares across the dose range, the Wegovy treatment overview covers the approved schedule in full.

Glucagon, GLP-1, and the difference between Wegovy and Ozempic

A question our prescribers hear regularly is whether Ozempic, being the same molecule, works by the same glucagon-suppressing mechanism. It does. Both Ozempic and Wegovy contain semaglutide; both bind the GLP-1 receptor and suppress glucagon in the same way. The critical difference is their licensed indication and approved dose. Ozempic is licensed in the UK for type 2 diabetes management, not weight loss. Wegovy is licensed for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure or obstructive sleep apnoea. Prescribing Ozempic for weight loss sits outside its licence, which affects how any complications would be managed and how supply is prioritised.

The oral form (Wegovy tablets, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management) works by the same receptor mechanism. The SNAC absorption enhancer in the tablet allows semaglutide to reach the bloodstream through the stomach lining. Glucagon suppression, gastric slowing and appetite reduction follow. The phase 3 OASIS 4 trial reported average weight loss of around 13.6% over 64 weeks among all participants, rising to roughly 17% in those who stayed fully adherent. If the injection route feels like a barrier, that option now exists, you can read about eligibility and the full process on the weight-loss treatments page.

What this means if you're considering treatment

Understanding that semaglutide affects glucagon, gastric emptying and brain appetite signals together helps explain why it works differently from calorie-counting alone. It's not bypassing normal physiology, it's restoring a hormonal signal the body already uses but struggles to sustain. That distinction matters to a lot of people who've tried other approaches and felt the biology working against them.

Semaglutide is a prescription-only medicine in the UK. A GPhC-registered prescriber assesses whether it's suitable based on your full health picture, not the BMI number alone. At nume, every consultation is read by a real prescriber the same day, not software. If you'd like to know whether you'd be eligible, the cost and what's included are covered separately, and the eligibility assessment itself is free. You're also welcome to look at what our clinical team brings to that process. For anyone in Scotland, the Aberdeen-region Wegovy page covers locally relevant access context. A fuller overview of how semaglutide behaves across the dose schedule is on the semaglutide page, and if you want to dig into the specifics of how the dose progression works, you can read about semaglutide 1 and semaglutide 2 in more detail. When you're ready to check whether treatment is right for you, the consultation is the place to start.